President Donald Trump directed the administration to speed up reviews of certain psychedelic drugs, including ibogaine, via an executive order meant to accelerate access to potential medical treatments. The order follows bipartisan attention to ibogaine’s use among veterans and advocates despite serious safety risks, and it came with high-profile participants in the Oval Office, including Health Secretary Robert F. Kennedy Jr. and conservative podcaster Joe Rogan. Rogan said he texted Trump information on ibogaine and received a response asking about FDA approval. The FDA is set to issue national priority vouchers next week for three psychedelics—creating a fast-tracking pathway that could compress review timelines from months to weeks. The agency is also taking steps intended to clear the way for the first-ever U.S. human trials of ibogaine. For higher education and research institutions, the development signals a near-term expansion of federally enabled psychedelic research pipelines, including study designs that may affect how universities recruit clinical partners and IRB-ready protocols.